Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Moderna, Inc.
  6. News
  7. Summary
    MRNA   US60770K1079

MODERNA, INC.

(MRNA)
  Report
Delayed Nasdaq  -  04:00 2022-12-08 pm EST
184.70 USD   +3.18%
04:59pS&P 500, Nasdaq snap losing streaks after jobless claims rise
RE
04:03pS&P 500 snaps losing streak on jobless claims rise
RE
03:58pFDA Authorizes Pfizer-BioNTech, Moderna COVID-19 Shots for Children as Young as Six Months
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Indonesia approves first home-grown COVID vaccine for emergency use - media

09/28/2022 | 05:22am EST
People receive COVID-19 boosters targeting Omicron

JAKARTA (Reuters) - Indonesia has approved its first domestically-produced COVID-19 vaccine for emergency use for people over 18, the chief of the country's food and drugs agency (BPOM) was quoted by news media as saying on Wednesday.

The Indovac vaccine has been developed by Indonesia's state-owned pharmaceutical company Bio Farma and the Baylor College of Medicine in Houston, Texas.

Penny Lukito, the head of BPOM, was cited by news portal CNN Indonesia as saying the approval was "given as a primary vaccine for adults."

Penny and a Bio Farma spokesperson did not immediately respond to requests for comment.

Bio Farma said this month it would produce 20 million doses of the vaccine in 2022 and 100 million doses by 2024. It has also said it has sought a halal certificate - which would make the vaccine permissible under Islam - from relevant authorities.

Indonesia is the world's biggest Muslim-majority nation.

Bio Farma chief Honesti Basyir said earlier this month that the vaccines were intended to "help reduce the nation's dependency on imported vaccines," adding 80% of Indovac is locally-sourced.

Indonesia, which reported one of the highest transmission rates of COVID-19 in the world last year, has used vaccines produced by China's Sinovac Biotech, Pfizer Inc and BioNTech as well as Moderna Inc.

Bio Farma has said it has also sought an emergency use approval from the World Health Organization (WHO).

Indonesia is also developing another home-grown vaccine called Inavac.

(Reporting by Stanley Widianto; Editing by Raju Gopalakrishnan)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 5.64% 171.81 Delayed Quote.-36.92%
MODERNA, INC. 3.18% 184.7 Delayed Quote.-31.67%
PFIZER, INC. 3.07% 51.78 Delayed Quote.-15.82%
All news about MODERNA, INC.
04:59pS&P 500, Nasdaq snap losing streaks after jobless claims rise
RE
04:03pS&P 500 snaps losing streak on jobless claims rise
RE
03:58pFDA Authorizes Pfizer-BioNTech, Moderna COVID-19 Shots for Children as Young as Six Mon..
MT
02:16pS&P 500 rebounds as investors take rate hike cues from jobless claims rise
RE
12:26pFDA approves Moderna, Pfizer bivalent COVID-19 vaccines for youngest kids
AQ
12:22pS&P 500 rebounds on tech boost; weekly jobless claims rise
RE
11:59aModerna Gets US Emergency Use Authorization for Bivalent Omicron Jab for Infants, Young..
MT
10:51aFDA clears updated COVID-19 vaccines for kids under age 5
AQ
10:39aModerna's COVID-19 Booster Vaccine Secures FDA Emergency Use Authorization for Children
MT
10:30aFDA Authorizes Updated Covid Vaccines For Kids as Young as 6 Months
DJ
More news
Analyst Recommendations on MODERNA, INC.
More recommendations
Financials (USD)
Sales 2022 19 089 M - -
Net income 2022 8 897 M - -
Net cash 2022 12 022 M - -
P/E ratio 2022 8,30x
Yield 2022 -
Capitalization 68 768 M 68 768 M -
EV / Sales 2022 2,97x
EV / Sales 2023 6,27x
Nbr of Employees 2 700
Free-Float 90,3%
Chart MODERNA, INC.
Duration : Period :
Moderna, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MODERNA, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 19
Last Close Price 179,00 $
Average target price 211,25 $
Spread / Average Target 18,0%
EPS Revisions
Managers and Directors
StÚphane Bancel Chief Executive Officer & Director
Stephen Hoge President
James M. Mock Chief Financial Officer
Noubar B. Afeyan Chairman
Juan Andres Chief Technical Operations & Quality Officer
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.-31.67%68 768
IQVIA HOLDINGS INC.-26.39%38 576
LONZA GROUP AG-38.60%36 912
ALNYLAM PHARMACEUTICALS, INC.29.52%28 460
SEAGEN INC.-22.79%22 161
CELLTRION, INC.-10.86%18 235